3 results
The primary study objective is to assess the effect of lanreotideAutogel 120mg administered every 28 days compared to placebo, onprogression-free survival in patients with well or moderatelydifferentiated non functioning entero-pancreatic endocrine…
Primary objectives:Safety for Dose Selection• To assess the safety and tolerability of PQ912Efficacy • To evaluate the efficacy of PQ912 on working memory and attentionSecondary Objectives:Safety• To assess the safety and tolerability of long-term…
To investigate the efficacy of lanreotide therapy as compared to placebo in patients with NFMA and positive pituitary somatostatin receptor imaging using Gallium-68 DOTATATE PET/CT, on tumor size.